Miami scientists at the University of Miami say mitochondrial DNA damage does not simply fade away inside the brain cells hit hardest by Parkinson’s disease. Instead, it keeps piling up in dopamine-producing neurons for months after the original insult. Working in mice, a team led by Carlos Moraes and Tania Arguello found a mechanism that could help explain why neurons in the substantia nigra steadily lose ground as people age.
In a peer-reviewed study published in PNAS, the group used a mitochondrially targeted endonuclease called mito‑PstI to trigger controlled double‑strand breaks in mitochondrial DNA inside dopamine neurons, then tracked how those genomes changed over time. High‑resolution sequencing uncovered large deletions and duplications that clustered around regulatory “hotspots,” and some deletions continued to grow even after mito‑PstI expression was shut off. The patterns indicate that defective mitochondrial genomes can clonally expand through replication‑dependent mechanisms, rather than coming only from new damage.
The team also probed the role of MGME1, an exonuclease that participates in mitochondrial DNA replication and maintenance. They found that deletions still appeared when MGME1 was absent, but they stopped building up over time, which separated the initial formation of deletions from their later expansion. “If this accumulation has a role in the development of Parkinson’s disease,” Moraes said, “we could direct efforts to control it,” according to the University of Miami. That result points straight at the replication machinery as a possible therapeutic target for blocking harmful mitochondrial DNA species from taking over vulnerable neurons.
The mitochondrial DNA pileup also depended on cell type. Glutamatergic neurons developed deletions after the experimental hit but did not show the same ongoing buildup, while dopaminergic neurons in certain brain regions saw deletion levels climb more than tenfold. On top of that, dopaminergic neurons in the substantia nigra showed an overall drop in healthy mitochondrial DNA copy number, a one‑two punch that could speed up functional decline. Technology Networks republished the team’s summary and linked to the original paper.
Context within Parkinson's research
Scientists have previously observed mitochondrial genome instability and loss of copy number in the substantia nigra of human Parkinson’s brains, and many have suspected that mitochondrial DNA changes help drive the selective vulnerability of these neurons. A landmark Nature Communications paper documented high levels of somatic mitochondrial DNA deletions in susceptible nigral neurons, and a recent systematic review in the European Journal of Medical Research highlighted mitochondrial DNA alterations as a unifying pathway in Parkinson’s. The new PNAS work adds a time‑lapse view, showing how deletions can both arise and clonally expand in specific neuronal subtypes.
What this means for treatments
Since the accumulation depends on replication factors such as MGME1, the authors argue that therapies which stabilize mitochondrial DNA replication or limit clonal expansion could sit alongside strategies that focus on protein aggregation or mitophagy. The work is preclinical and uses genetically engineered mice, so both the authors and outside commentators note that the findings will need to be confirmed in human tissue and eventually in patients before anyone talks about clinical trials. As laid out in PNAS, the study opens new paths for targeting mitochondrial genome dynamics in neurodegenerative disease.
The project was led at the University of Miami Miller School of Medicine by Moraes and Arguello and was published this month. The lab says it will keep probing how mitochondrial genome behavior shapes neuron health. Local clinicians and researchers at UHealth and related centers may use these mechanistic clues to prioritize biomarkers and early‑stage interventions for Miami‑area patients living with Parkinson’s disease, the university’s release says.
